Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 03, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 1,850,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,274 pence per share.
- Transaction Date: August 03, 2007.
Material Changes and Share Capital Status
Following the repurchase, the company's share capital structure is as follows:
- Treasury Shares Held: 338,049,158 shares.
- Treasury Percentage: 5.95% of total voting rights.
- Shares in Issue: 5,683,533,041 shares (excluding Treasury shares).
The number of shares in issue represents the total voting rights and serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (1,850,000 shares at 1,274 pence) against the company's cash position in other reports.
- Confirm the updated total voting rights denominator (5,683,533,041) for compliance with disclosure thresholds.
- Note that the company intends to hold the repurchased shares in Treasury rather than canceling them immediately.